The relationship between serum level of N-terminal pro-B-type natriuretic peptide and nutritional status, and inflammation in chronic hemodialysis patients

Clinical Nephrology

Volumn 73, Issue 1, 2010, Pages 14-20

  Bednarek Skublewska, Anna ^a,b   Zaluska, W ^a   Ksiazek, A ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b NONE   (Poland)

Author keywords

Hemodialysis; Hydration; Inflammation; N terminal pro B type natriuretic peptide; Nutrition

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN; INTERLEUKIN 6; TRANSFERRIN; TUMOR NECROSIS FACTOR RECEPTOR 1; UREA;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; BODY FLUID COMPARTMENT; BODY MASS; CATABOLISM; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; HYDRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MYOCARDIAL DISEASE; NUTRITIONAL STATUS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; WEIGHT GAIN;

EID: 74049135683     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73014     Document Type: Article

References (32)

1. Anwaruddin S, Lioyd-Jones DM, Baggish A et al. Renal function, congestive heart failure, and amino-terminal pro brain natriuretic peptide measurements: results from the pro BNP investigation of Dyspnea in the Emergency Department. (PRIDE) Study. J Am Coll Cardiol. 2006; 447: 91-97.
2. Apple F, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk of NT-pro BNP natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end stage renal disease for all-cause death. Clin Chem. 2004; 50: 2279-2285.
3. Bergström J. Why are dialysis patients malnourished. Am J Kidney Dis. 1995; 26: 229-241.
4. Bergström J, Wang T, Lindholm B. Factors contriuting catabolism in end-stage renal disease patients. Miner Electrolyte Metab. 1998; 24: 92-101.
5. Cameron SJ, Green GB. Cardiac Biomarkers in renal Disease: The Fog Is Slowly Lifting. Clin Chem 2004; 50: 2233-2235.
6. Charlson ME, Popei P, Ales KL, MacKenzie CR. A new method of classifying comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
7. Daugirdas JT. Second generation logarithmic estimates at single poor variable volume Kt/V an analysis of error. J Am Soc Nephrol. 1993; 4: 1205-1213.
8. Flemmer M, Rajab H, Methena T, Paulson J, Perkins S, Whelan T, Chiu R, McCullough PA. Blood B-type natriuretic peptide and dialysis: present assessment and future analyses. South Med. 2008; 101: 1094-1100.
9. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy morbidity and mortality in end stage renal disease. Am I Kidney Dis. 1996; 28: 53-61.
10. Hammerer-Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clin Lab. 2001; 47: 265-277.
11. Hunt PJ, Richards AM, Nicholls MG et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287-296.
12. Katz AM. Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. J Cell Mol Med. 2003; 7: 1-10.
13. Leowattana W, Ong-Ajyooth L, Taruangsri P, Pokum S. Circulating N- terminal pro brain natriuretic peptide and cardiac troponin T in chronic dialysis patients. JMedAssoc Thai. 2003; 86: 52-58.
14. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-1143.
15. Madsen LH, Ladefoged S, Corell P, Schou M, Hildegrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007; 71: 548-554.
16. Maisel A, Mueller C, Adams K Jr et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J heart Fail. 2008; 10: 824-839.
17. Moissl UM, Wabel P, Chamney PW et al. Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas. 2006; 27: 921-933.
18. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction-comparison of the diagnosis accuracy of brain peptide (BNP) and amino terminal pro BNP (NT-proBNP). Clin Chem Lab Med. 2004; 42: 159-163.
19. NKF-K/DOQI. Nutrition Work Group Clinical Practice Guidelines for nutrition in chronic renal failure. New York: National Kidney Fundation; 2001. p. 75-80.
20. Racek J, Kralova H, Trefil L, Rajdl D, Eiselt J. Brain natriuretic peptide and N-terminal pro BNP in chronic haemodialysis patients. Nephrol Clin Pract. 2006; 103: 162-172.
21. Sarkar SR, Kotanko P, Levin NW. Interdialytic weight gain: Implications in hemodialysis patients. Seminars in Dialysis. 2006; 19: 429-433.
22. Sheen V, Bhalla V, Tulua-Tata A, Bhalla M, Weiss D, Chiu A, Abdeen O, Mullaney S, Maisel A. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J. 2007; 153: 244.e1-5.
23. Sommerer C, Beimler J, Schwenger V, Heckele N et al. Cardiac biomarkers and survival in hemodialysis patients. Eur J Clin Invest. 2007; 37: 350-356.
24. Spanaus KS, Kronenberg F, Ritz E et al. B-type natriuretic peptides predict the progression of nondiabetic chronic kidney disease: The mild t-moderate kidney disease study. Clin Chem. 2007; 53: 1264-1272.
25. Stenvinkel P. Inflammation in end-stage renal failure could it be treated. Nephrol Dial Trans. 2002; 17: 33-38.
26. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899-1911.
27. Strassburg S, Anker SD. Metabolic and immunological derangements in cardiac cachexia: where to from here. Heart Fail Rev. 2006; 11: 57-60.
28. Tattersall J. Bioimpedance analysis in dialysis: state of the art and what we can expect. Blood Purif. 2009; 27: 70-74.
29. Vickery S, Price CP, John RI et al. B-type natriuretic peptide (BNP) and amino-terminal pro BNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005; 46: 610-620.
30. Vickery S, Web MC, Price CP et al. Prognostic value of cardiac biomarkers for death in non-dialysis chronic kidney disease population. Nephrol Dial Transplant. 2008; doi:10.1093/ndt/gfn 341.
31. Wabel P, Moissl U, Chamney P et al. Towards improved cardiovascular management: the necessity of combining blood pressure and fluid overload. Nephrol Dial Transplant. 2008; doi:10.1093/ndt/gfn 228.
32. Zoccali C, Mallamaci F et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001; 12: 1508-1515.